Dehydroglyasperin C
Modify Date: 2025-08-21 23:59:40
Dehydroglyasperin C structure
|
Common Name | Dehydroglyasperin C | ||
|---|---|---|---|---|
| CAS Number | 199331-35-6 | Molecular Weight | 354.40 | |
| Density | 1.3±0.1 g/cm3 | Boiling Point | 588.6±50.0 °C at 760 mmHg | |
| Molecular Formula | C21H22O5 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 309.8±30.1 °C | |
Use of Dehydroglyasperin CDehydroglyasperin C, a isoflavone, is a potent NAD(P)H:oxidoquinone reductase (NQO1) and phase 2 enzyme inducer. Dehydroglyasperin C has antioxidant, neuroprotective, cancer chemopreventive, and anti-inflammatory activities[1][2][3]. |
| Name | 4-(7-hydroxy-5-methoxy-6-(3-methylbut-2-en-1-yl)-2H-chromen-3-yl)benzene-1,3-diol |
|---|---|
| Synonym | More Synonyms |
| Description | Dehydroglyasperin C, a isoflavone, is a potent NAD(P)H:oxidoquinone reductase (NQO1) and phase 2 enzyme inducer. Dehydroglyasperin C has antioxidant, neuroprotective, cancer chemopreventive, and anti-inflammatory activities[1][2][3]. |
|---|---|
| Related Catalog | |
| In Vitro | Dehydroglyasperin C (0.1-1 μM; 24 h) blocks the PDGF-induced progression through the G0/G1 to S phase of the cell cycle, and down-regulates the expression of CDK; 2, cyclin E, CDK4 and cyclin D1. Dehydroglyasperin C significantly attenuates PDGF-stimulated phosphorylation of PDGF receptor-β, phospholipase C-γ1, AKT and extracellular-regulated kinase 1/2, and DGC inhibits cell migration and the dissociation of actin filaments by PDGF[1]. Dehydroglyasperin C (0.1-1 μM; 24 h) treatment significantly decreases PDGF-induced cell number and DNA synthesis in a dose-dependent manner without any cytotoxicity in human aortic smooth muscle cells (HASMC)[1]. Cell Cycle Analysis[1] Cell Line: Human aortic smooth muscle cells (HASMC) Concentration: 0.1 μM, 0.5 μM, 1 μM Incubation Time: 24 hours Result: Blocked the PDGF-induced progression through the G0/G1 to S phase of the cell cycle. Western Blot Analysis[1] Cell Line: Human aortic smooth muscle cells (HASMC) Concentration: 0.1 μM, 0.5 μM, 1 μM Incubation Time: 24 hours Result: Down-regulated the expression of CDK; 2, cyclin E, CDK4 and cyclin D1. |
| In Vivo | In ICR mice, Dehydroglyasperin C (5 mg/kg; once) combined with CCl4 shows reduced lipid droplet formation in liver tissue, as assessed by histological examination. Further, DGC demonstrated a slight protective effect against centrilobular injury caused by CCl4 injection, perhaps through suppression of CYP2E1 expression[4]. |
| References |
| Density | 1.3±0.1 g/cm3 |
|---|---|
| Boiling Point | 588.6±50.0 °C at 760 mmHg |
| Molecular Formula | C21H22O5 |
| Molecular Weight | 354.40 |
| Flash Point | 309.8±30.1 °C |
| Exact Mass | 354.146729 |
| PSA | 79.15000 |
| LogP | 6.48 |
| Vapour Pressure | 0.0±1.7 mmHg at 25°C |
| Index of Refraction | 1.637 |
| Hazard Codes | Xi |
|---|
| 1,3-Benzenediol, 4-[7-hydroxy-5-methoxy-6-(3-methyl-2-buten-1-yl)-2H-1-benzopyran-3-yl]- |
| 4-((R)-7-Hydroxy-5-methoxy-6-(3-methyl-but-2-enyl)-1-benzopyran-3-yl)-benzene-1,3-diol |
| 4-[7-Hydroxy-5-methoxy-6-(3-methyl-but-2-enyl)-2H-1-benzopyran-3-yl]-benzene-1,3-diol |
| 4-[(R)-7-Hydroxy-5-methoxy-6-(3-methyl-but-2-enyl)-1-benzopyran-3-yl]-benzene-1,3-diol |
| 4-[7-Hydroxy-5-methoxy-6-(3-methyl-2-buten-1-yl)-2H-chromen-3-yl]-1,3-benzenediol |